Diabetic nephropathy (DN) refers to kidney disease caused by diabetes. DN is a leading cause of chronic kidney disease (CKD), and is associated with high morbidity, mortality, and cost. Use of pharmacotherapy for DN varies by disease severity, physician specialty, and CKD stage. Physicians consider management of DN challenging because current therapies manage only the complications of DN. Currently available therapies have limited efficacy, are unable to treat the underlying disease, and prevent progressive renal decline in patients. Our Current Treatment deep dive content investigates the current prescribing practices for DN and focuses on the various factors driving the these treatment decisions.
- Do treatment decisions for DN differ based on disease progression and the specialty of the treating physician?
- Which attributes are most important in choosing drugs for the management of DN patients?
- How do physicians perceive standard of care therapies such as ACE inhibitors or ARBs for DN?
- What is the level of satisfaction among physicians with currently available DN treatments? What is the level of familiarity and interest in products in the development pipeline?